ArticleFrontiers in microbiology2023
Comparison of
Article in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 6 citations in OpenAlex.
- The Use of Blue Light as an Antimicrobial Treatment Against Staphylococcus aureus: A Systematic Review.Lasers in surgery and medicine · 2026Pooled it
- Antimicrobial Efficacy of Endogenous Blue Light Photoinactivation (400-470 nm) AgainstMedical sciences (Basel, Switzerland) · 2026Pooled it
- Biochanin A, a Plant Isoflavone, Disrupts Peptidoglycan Biosynthesis by DownregulatingAntibiotics (Basel, Switzerland) · 2026Article
- Quantification of Antibiotic Diffusion in Biofilms Using Gold Nanostar Surface-enhanced Raman Spectroscopy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Histopathological changes and inflammatory and cell death pathways in the lungs of Balb/c mice with pneumonia induced by different concentrations ofAnatomy & cell biology · 2025Article
- Lights out for Superbugs: Is antimicrobial blue light a potential approach for future infection Control?Advanced drug delivery reviews · 2025Review
- Probing the Coupled Equilibria between Metal Nanoparticles, Antibiotics and Components of the Extracellular Matrix in Biofilms with SERS.Biomacromolecules · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bacterial biofilms readily develop on all medical implants, including percutaneous osseointegrated (OI) implants. With the growing rate of antibiotic resistance, exploring alternative options for managing biofilm-related infections is necessary. Antimicrobial blue light (aBL) is a unique therapy that can potentially manage biofilm-related infections at the skin-implant interface of OI implants. Antibiotics are known to have antimicrobial efficacy disparities between the planktonic and biofilm bacterial phenotypes, but it is unknown if this characteristic also pertains to aBL. In response, we developed experiments to explore this aspect of aBL therapy. Methods: We determined minimum bactericidal concentrations (MBCs) and antibiofilm efficacies for aBL, levofloxacin, and rifampin against Results: aBL had the most significant efficacy disparity between the planktonic and biofilm phenotypes (a 2.5 log Discussion/conclusion: We determined that phenotype is an important characteristic to consider when determining aBL parameters for treating OI implant infections. Future research would benefit from expanding these findings against clinical
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.